GLP-1 prescribing
GLP-1 medicines each month, by drug, as published - NHS prescription items in England and the number of users in Denmark. Data as of 9 November 2026.
tirzepatide (Mounjaro)semaglutide (Ozempic, Wegovy, Rybelsus)dulaglutide (Trulicity)liraglutide (Victoza, Saxenda and generics)Wegovy (semaglutide)Ozempic (semaglutide)Mounjaro (tirzepatide)Saxenda (liraglutide)
England
items per month · data to Aug 2026NHS Business Services Authority: NHS prescription items written in England and dispensed in the community in the month, summed over all prescribers for each BNF chemical substance (tablets and injections of a drug counted together); private prescriptions and hospital-dispensed medicines are not included
Released 20 Oct 2026
Denmark
users per month · data to Sep 2026Danish Health Data Authority: people who bought the product on prescription in the month in primary care, all sales including private, by product (Wegovy and Ozempic are both semaglutide, Mounjaro is tirzepatide, Saxenda is liraglutide); figures the authority suppresses (fewer than 5) are left without a figure
Released 9 Nov 2026 · next 8 Dec 2026
Revised by the source: 3 earlier weeks since 16 Oct 2026; the largest, the week to Aug 2026, from 6,530 to 6,564
| Drug | Latest month | Figure | Month before | Change on month before | Source release |
|---|---|---|---|---|---|
| England, tirzepatide (Mounjaro) | Aug 2026 | 342,252 items | 367,597 items | -6.9% | 20 Oct 2026 |
| England, semaglutide (Ozempic, Wegovy, Rybelsus) | Aug 2026 | 144,757 items | 154,448 items | -6.3% | 20 Oct 2026 |
| England, dulaglutide (Trulicity) | Aug 2026 | 37,162 items | 42,098 items | -11.7% | 20 Oct 2026 |
| England, liraglutide (Victoza, Saxenda and generics) | Aug 2026 | 1,408 items | 1,587 items | -11.3% | 20 Oct 2026 |
| Denmark, Wegovy (semaglutide) | Sep 2026 | 102,360 users | 106,600 users | -4.0% | 9 Nov 2026 |
| Denmark, Ozempic (semaglutide) | Sep 2026 | 69,828 users | 69,153 users | +1.0% | 9 Nov 2026 |
| Denmark, Mounjaro (tirzepatide) | Sep 2026 | 6,721 users | 6,564 users | +2.4% | 9 Nov 2026 |
| Denmark, Saxenda (liraglutide) | Sep 2026 | 428 users | 410 users | +4.4% | 9 Nov 2026 |
Download the whole series: CSV · JSON, with every release collected
Method note
The figures are NHS prescription items for four GLP-1 receptor agonists — tirzepatide, semaglutide, dulaglutide and liraglutide — written in England and dispensed in the community each month, as published by the NHS Business Services Authority. An item is one drug on one prescription form. It is not a patient, and one patient may have several items in a month. Tablets and injections of the same drug are counted together, because the source records the drug and not the form at this level.
Two things sit outside these figures. Private prescriptions are not in the dataset, and in the United Kingdom most tirzepatide supplied for weight loss has been private. A prescription also records no indication, so use for type 2 diabetes and use for weight management cannot be separated: Mounjaro, generic tirzepatide and semaglutide serve both.
The SNOMED edition of the dataset begins in November 2020. Each month is published about seven weeks after it ends. The latest three months are read again on every run, so any revision the NHS Business Services Authority makes is recorded below.
Denmark's figures are the Danish Health Data Authority's count of people who bought each product on prescription in primary care in the month, from its monthly publication on weight-loss and diabetes medicines. They include privately paid prescriptions. They are given by brand — Wegovy and Ozempic are both semaglutide, Mounjaro is tirzepatide, Saxenda is liraglutide — and counts of fewer than five are suppressed by the authority. People are counted, not prescriptions, so Denmark's figures cannot be set against England's items. Each card has its own scale.
Sources and licences
- England: NHS Business Services Authority, English Prescribing Dataset (EPD) with SNOMED code. Vintage used: the release of 20 Oct 2026. NHS prescription items written in England and dispensed in the community in the month, summed over all prescribers for each BNF chemical substance (tablets and injections of a drug counted together); private prescriptions and hospital-dispensed medicines are not included. Licence: Open Government Licence v3.0. Source: NHSBSA, English Prescribing Dataset, licensed under the Open Government Licence v3.0.
- Denmark: Danish Health Data Authority (Sundhedsdatastyrelsen), Vaegttabs- og diabetesmedicin, table 1. Vintage used: the release of 9 Nov 2026. Next release: 8 Dec 2026, as announced by Sundhedsdatastyrelsen. People who bought the product on prescription in the month in primary care, all sales including private, by product (Wegovy and Ozempic are both semaglutide, Mounjaro is tirzepatide, Saxenda is liraglutide); figures the authority suppresses (fewer than 5) are left without a figure. Licence: Free reuse with attribution, under the authority's terms for its statistics. Kilde: Sundhedsdatastyrelsen.
The Netherlands publishes GLP-1 use by year (GIPdatabank), Germany quarterly reports in PDF and the United States quarterly Medicaid data, so they are not in this tracker.
Revisions
Changes a source has made to its own past figures since this tracker began collecting.
- 10 Nov 2026, Denmark, Wegovy (semaglutide): 2 earlier period(s) revised; the largest change was Feb 2026, from 101,828 to 101,961.
- 10 Nov 2026, Denmark, Ozempic (semaglutide): 2 earlier period(s) revised; the largest change was Feb 2026, from 56,561 to 56,605.
- 10 Nov 2026, Denmark, Mounjaro (tirzepatide): 2 earlier period(s) revised; the largest change was Feb 2026, from 4,620 to 4,625.
- 16 Oct 2026, Denmark, Wegovy (semaglutide): 1 earlier period(s) revised; the largest change was Aug 2026, from 106,332 to 106,600.
- 16 Oct 2026, Denmark, Saxenda (liraglutide): 1 earlier period(s) revised; the largest change was Aug 2026, from 409 to 410.
- 16 Oct 2026, Denmark, Ozempic (semaglutide): 1 earlier period(s) revised; the largest change was Aug 2026, from 68,965 to 69,153.
- 16 Oct 2026, Denmark, Mounjaro (tirzepatide): 1 earlier period(s) revised; the largest change was Aug 2026, from 6,530 to 6,564.
Download
CSV of the whole series · JSON, with every release collected